Hand-selected to devise account management, launch, and contracting strategies for a buy & bill, injectable oncology drug, in addition to educating large community practice accounts on reimbursement best practices in the TX, AR, OK, MO, KS, NE, WI, ND, SD, CO, UT, NM, AZ, CA, WA, OR, ID, HI, AK territories for a startup company. Identified and developed relationships with Key Opinion Leaders. Key accounts include ION, Onmark, US Oncology, OncoEMR, INOMED, Flatiron, Texas Oncology, Rocky Mountain, Utah Cancer Specialists, PacShores, CCK, MOHA, WashU, and HOG. Collaborated with marketing, brand, legal, regulatory, and sales leadership in the development of pull-through strategies and reimbursement education programs. Oversee 6 indirect sales representatives reports, providing coaching on pull-through messaging strategies.Key Achievements: Catapulted Quarter over Quarter growth 2500% for a new antiemetic, Sustol despite market saturation by attaining a temporary J-code and focusing on largest account, Cancer Centers of Kansas.  Landed several major accounts, including OK Cancer Specialists and Research Institute Tulsa, Medical Oncology and Hematology Associates in Des Moines, Utah Cancer Specialists, PacShores in Long Beach, CA, and Desert Hematology / Oncology in Palm Springs, and Austin Cancer Centers. Instrumental in 2 separate, major accounts converting from Aloxi to Sustol by developing 3 highly regarded Key Opinion Leaders in the Midwest focused on reaching C-Suite and Nurse Managers and adding Sustol to Electronic Medical Records to increase utilization. Currently developing an advisory board comprised of pharmacy directors from large Oncology Practices to increase knowledge of market and form trusted relationships with key decision makers. Promoted from Area Business Manager to Regional Account Manager in less than one year due to proven ability to convert large accounts through exceptional relationships with high-level decision makers.

Promoted to grow the oncology and urology with prostate cancer infusion business by gaining access to CEOs, CFOs, physicians, nurses, billing managers, and practice managers in oncology and urology practices in the KS, AR, OK, MO, and CO territory. Assisted group practices with establishing advanced prostate cancer treatment centers for patient infusions. Met with C-level decision makers to communicate revenue potential while promoting patient satisfaction through one location services. Educated staff and office management on the buy and bill model, billing principles, and establishing infusion protocols. Identified and formed trusted relationships with Key Opinion Leaders to serve as product advocates. Coached 3 indirect sales representatives and held POA meetings to discuss pull-through strategies.Key Achievements: Realized 25% growth in first half of 2015, 12% growth over 2nd half of 2014, and 16% increase in 2013 by establishing advanced prostate cancer treatment centers with several large group practices, including Arkansas Urology, Kansas City Urology, Wichita Urology, and Urologic Specialists in Tulsa, which resulted in #2 ranking and winning the Circle of Excellence Award. Decreased failure rate from 40% to 20% in one quarter with the Kansas City Blood Center by providing in-depth training for cell collection and re-educating on best practices. Increased utilization of Provenge by University of Kansas following discontinuation of therapy due to failure rates.  Selected to serve on, provide valuable input to, and assist in the development of key marketing pieces as a member of the Field Marketing Advisory Team. Requested by senior management to represent the company at American Urological Association, ASCO, and LUGPA meetings.

-Immunotherapy sales to oncologists, and urologists with a focus on prostate cancer for the state of Kansas and Missouri -Finished #2 in the nation for 2013 - 2013 Circle of Excellence award trip winner -2013 6.7 million in sales -Member of Field Marketing Advisory Team

Amgen Biotech, Inc Kansas CitySr. Biopharmaceutical Representative• Hematology/ Oncology specialty sales focusing on bone metastases, chemotherapy-induced anemia, and ITP.• 2011 Top Performer: Top 25%• 2011 Over $8M in sales across 3 products• 2011 Team Excellence Award Winner• 2011 Rank of 24/116• Successful launch of Xgeva 2010-2011• 2011 Xgeva Field Product Lead

Sanofi-Aventis Pharmaceuticals Washington, DCOncology Specialty Sales: Eloxatin• Specialty sales representative focusing on colorectal cancer in adult populations. Work teaching institutions community practices, hospitals, and military accounts. Work with fellows, hem/oncs, and pharmacists to promote my products.• 2007 Performance Index 102.2%• 2009 Performance Index 106%• 2009 Sales Sanofi-Aventis Pharmaceuticals Washington, DCOncology Specialty Sales: Elitek Specialty sales representative focusing on hematologic malignancies in adult and pediatric populations. Work only in dedicated teaching instituions and military accounts. Work with fellows, hem/oncs, pharmacists to promote my products.• OFAB Representative: Oncology Field Advisory Board representative for my team. I attend meetings to help decide marketing tools and messages, address issues for the team.• 2006 Performance Index 104.4%